Skip to Main Content
Skip Nav Destination

A Multiomics-Informed HLA Signature Predicts Immunotherapy Response

June 12, 2024

Major Finding: A neoantigen-favoring HLA signature predicts immunotherapy response in clear-cell renal cell carcinoma.

Concept: A cross-omics machine learning model resolved a signature reflecting neoantigen-specific HLA alleles.

Impact: Combination treatment with immunotherapy and a CD40 agonist may be synergistic in renal cell carcinoma.


You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal